First Report of Vedolizumab-Associated Recall Urticaria in a Case Report and Literature Review
Why Hives Return to Old Injection Spots
This case report and literature review describes the first documented instance of vedolizumab-associated recall urticaria in a 25-year-old m…
A new case report reveals a rare skin reaction where hives return strictly to past injection sites.
Vedolizumab plus curcumin improves remission in moderate-to-severe ulcerative colitis versus vedolizumab alone.
Could adding curcumin to your current ulcerative colitis treatment help you reach remission faster?
This multicenter, double-blind randomized controlled trial enrolled 159 patients with moderate-to-severe ulcerative colitis. The study compa…
Adding curcumin to ulcerative colitis treatment helped more patients reach symptom remission faster than using standard drugs alone.
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response
Can New Drug Combinations Offer Hope for Crohn's Disease Sufferers?
Phase 4 trial investigates vedolizumab with adalimumab or ustekinumab in Crohn's. Primary endpoint: endoscopic response at 26 weeks.
Adults with moderate to severe Crohn's disease may find new relief by combining vedolizumab with adalimumab or ustekinumab before continuing…